Literature DB >> 27128184

Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.

Milan Subedi1, Il Minn2, Jianbo Chen1, YunHye Kim1, Kiwon Ok1, Yong Woo Jung1, Martin G Pomper2, Youngjoo Byun1,2,3.   

Abstract

Cell surface biomarkers such as prostate-specific membrane antigen (PSMA) and hepsin have received considerable attention as targets for imaging prostate cancer (PCa) due to their high cell surface expression in such tumors and easy access for imaging probes. Novel amidine-containing indole analogs (13-21) as hepsin inhibitors were designed and synthesized. These compounds showed in vitro inhibitory activity against hepsin with IC50 values from 5.9 to 70 μM. Based on the SAR of amidine-derived analogs, the novel heterobivalent compound 30, targeting both hepsin and PSMA, was synthesized by linking compound 18 with Lys-urea-Glu, the key scaffold for the specific binding to PSMA, followed by the conjugation of the optical dye SulfoCy7. Compound 30 exhibited inhibitory activities against PSMA and hepsin, with IC50 values of 28 nM and 2.8 μM, respectively. In vitro cell uptake and preliminary in vivo optical imaging studies of 30 showed selective binding and retention in both PSMA and hepsin high-expressing PC3/ML-PSMA-HPN cells as compared with low-expressing PC3/ML cells.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Hepsin; Heterobivalent ligands; Molecular imaging; PSMA; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27128184      PMCID: PMC4936276          DOI: 10.1016/j.ejmech.2016.04.033

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  28 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Authors:  Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

3.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.

Authors:  Mindy I Davis; Melanie J Bennett; Leonard M Thomas; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

4.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Authors:  Andrew J Vickers; Cathee Till; Catherine M Tangen; Hans Lilja; Ian M Thompson
Journal:  J Natl Cancer Inst       Date:  2011-02-24       Impact factor: 13.506

5.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

6.  Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).

Authors:  Bradley A Katz; Christine Luong; Joseph D Ho; John R Somoza; Erik Gjerstad; Jie Tang; Steven R Williams; Erik Verner; Richard L Mackman; Wendy B Young; Paul A Sprengeler; Hedy Chan; Kyle Mortara; James W Janc; Mary E McGrath
Journal:  J Mol Biol       Date:  2004-11-19       Impact factor: 5.469

7.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

8.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

Authors:  Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper
Journal:  J Med Chem       Date:  2008-07-19       Impact factor: 7.446

9.  Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.

Authors:  Vincenzo N Talesa; Cinzia Antognelli; Chiara Del Buono; Fabrizio Stracci; Maria R Serva; Emanuele Cottini; Ettore Mearini
Journal:  Cancer Biomark       Date:  2009       Impact factor: 4.388

10.  Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.

Authors:  Xi Tang; Sumit S Mahajan; Liem T Nguyen; François Béliveau; Richard Leduc; Julian A Simon; Valeri Vasioukhin
Journal:  Oncotarget       Date:  2014-03-15
View more
  3 in total

1.  Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  J Med Chem       Date:  2019-12-02       Impact factor: 7.446

Review 2.  Cochlear protein biomarkers as potential sites for targeted inner ear drug delivery.

Authors:  James G Naples; Lauren E Miller; Andrew Ramsey; Daqing Li
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 3.  The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.

Authors:  Eline A M Ruigrok; Wytske M van Weerden; Julie Nonnekens; Marion de Jong
Journal:  Pharmaceutics       Date:  2019-10-29       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.